Elanix Biotechnologies

We are a tissue regeneration company dedicated to using innovative cell technologies, advancing patient wound care and healing processes

Elanix develops and markets progenitor cell-based products to help regenerate tissue and promote healing in the treatment of burns, gynecological and dermatological conditions. The Company is headquartered in Berlin, Germany with offices in Epalinges, Canton Vaud, Switzerland and Hamburg, Germany, and listed on the Frankfurt stock exchange under the symbol ELN.

New Equity Research

Flash Note published after live webcast

Wednesday August 8th, 2018 – goetzpartners securities Limited published a Flash Note report after live investor webcast by Elanix management that included financial outlook.


Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix enhances the activity of progenitor cells with proprietary cytokine formulations to create unique cell therapy products and procedures.


Elanix owns two advanced skin care products, GYNrepair® and SKINrepair®, marketed in Switzerland since 2012 for dermatological and gynecological applications.

Elanix is developing a bioresorbable & bioactive skin dressing derived from progenitor skin fibroblasts to accelerate regeneration and improve quality of skin following acute burns.


Sincopharm SA